P1.01-102 Retrospective Analysis of Immune Checkpoint Inhibitors in Patients With EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.659
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Comprehensive Analysis of EGFR Signaling Pathways in Japanese Patients With Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2009English

P3.01-11 Depression and Inflammation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors

Lung Cancer Management
2019English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology
OncologyPharmacology
2019English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy